Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has revealed its participation in several key investor conferences scheduled for Spring 2024, including the LD Micro Invitational in New York and BIO International Convention in San Diego. Additionally, XORTX has announced a six-month investor relations agreement with LHA Investor Relations, signaling a proactive approach to stakeholder engagement. The company specializes in developing treatments for progressive kidney diseases and is currently advancing two clinical-stage products targeting purine metabolism disorders.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
